NCT04827251Completed
Effects of Espresso on Platelet Aggregability in Patients with Coronary Artery Disease
Evaluation of the Effect of Espresso on Platelet Aggregability in Patients with Coronary Artery Disease
Source: ClinicalTrials.gov · Last updated 13 Feb 2025
Brief summary (registry, in English)
Discovered thousands of years ago, coffee is among the most consumed beverages in the world. The relationship between coffee and cardiovascular risk, more specifically coronary artery disease, is controversial. Platelet aggregation and its relationship with coffee is also controversial. The investigators propose this study to evaluate the relationship between coffee and platelet aggregability in patients with coronary artery disease.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 29 (actual)
- First submitted
- 19 Mar 2021
- Start date
- 1 Sept 2022
- Primary completion date
- 25 Nov 2024
- Lead sponsor
- University of Sao Paulo
- Diseases
- Coronary artery disease
- NCT number
- NCT04827251
What you commit to
- Study type: Interventional
- Participants enrolled: 29
- From 1 Sept 2022 to the primary completion date, 25 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of P2Y12 inhibitor;
Lab values
- Serum creatinine dosage \> 2.5 mg/dl;
- Hemoglobin \<12 g/% for men and \<11 g/% for women;
- Platelets \<100,000 or \>400,000/mm3;
- Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT) with values above the upper limits of normality;
- Ventricular dysfunction (left ventricular ejection fraction \<45%).
Other
- Leukocytosis \>12,000/mm3;
- Fasting glycemia \>126mg/dl;
- Consumption of more than 30 grams of alcohol per day;
- Active smoking or ex-smoking for less than 2 years;
Who the study is looking for
- Age 20 to 80 years;
- Coronary artery disease documented by coronary angiography;
- Use of aspirin 100mg.
Age in the registry: 20 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heart Institute (InCor) / University of São Paulo Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.